XJPX
8086
Market cap1.57bUSD
Jul 10, Last price
1,546.50JPY
1D
-0.87%
1Q
-5.38%
Jan 2017
21.01%
Name
Nipro Corp
Chart & Performance
Notes
No notes on this company yet
Write a private note on this company, for your eyes only
Profile
Nipro Corporation, along with its affiliated companies, operates across three primary business divisions: medical devices, pharmaceuticals, and pharmaceutical packaging. The company's Medical Device sector is dedicated to the development, production, and distribution of an extensive selection of disposable medical products. These offerings encompass specialized items for renal treatment, interventional procedures and anesthesia, injection and infusion therapies, dialysis, cardiopulmonary support, diabetes management, and cell culture applications. This division also markets products associated with artificial organs, as well as generic and kit-based medical supplies. Within its Pharmaceutical division, Nipro delivers innovative pharmaceutical combination products, such as dual chamber bags, pre-filled syringes, and half-type kits. It further extends its services through contract manufacturing for orally administered medications, injectable solutions, and topical preparations. The Pharma Packaging segment is focused on providing a comprehensive array of glass packaging solutions. This includes vials, ampoules, syringes, cartridges, and glass tubes. Additionally, this division manufactures glass forming machinery, glass bulbs for vacuum flasks, and various other essential pharmaceutical packaging components, such as rubber stoppers. An 'Other' business activity involves the provision of thermostable enzymes, which are vital for clinical chemistry applications. Nipro also offers business management services. Established in Osaka, Japan, in 1947, Nipro Corporation now serves a wide international customer base, spanning Japan, the Americas, Europe, and other regions across Asia.
Valuation
Title JPY in thousands, except ratios and share amounts | FY | FY | FY | FY | FY | FY | FY | FY | FY | FY |
|---|---|---|---|---|---|---|---|---|---|---|
| 2026‑03 | 2025‑03 | 2024‑03 | 2023‑03 | 2022‑03 | 2021‑03 | 2020‑03 | 2019‑03 | 2018‑03 | 2017‑03 | |
| Income | ||||||||||
Revenues | ||||||||||
Cost of revenue | ||||||||||
Unusual Expense (Income) | ||||||||||
NOPBT | ||||||||||
NOPBT Margin | ||||||||||
Operating Taxes | ||||||||||
Tax Rate | ||||||||||
NOPAT | ||||||||||
Net income | ||||||||||
Dividends | ||||||||||
Dividend yield | ||||||||||
Proceeds from repurchase of equity | ||||||||||
BB yield | ||||||||||
| Debt | ||||||||||
Debt current | ||||||||||
Long-term debt | ||||||||||
Deferred revenue | ||||||||||
Other long-term liabilities | ||||||||||
Net debt | ||||||||||
| Cash flow | ||||||||||
Cash from operating activities | ||||||||||
CAPEX | ||||||||||
Cash from investing activities | ||||||||||
Cash from financing activities | ||||||||||
FCF | ||||||||||
| Balance | ||||||||||
Cash | ||||||||||
Long term investments | ||||||||||
Excess cash | ||||||||||
Stockholders' equity | ||||||||||
Invested Capital | ||||||||||
ROIC | ||||||||||
ROCE | ||||||||||
| EV | ||||||||||
Common stock shares outstanding | ||||||||||
Price | ||||||||||
Market cap | ||||||||||
EV | ||||||||||
EBITDA | ||||||||||
EV/EBITDA | ||||||||||
Interest | ||||||||||
Interest/NOPBT | ||||||||||